<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462877</url>
  </required_header>
  <id_info>
    <org_study_id>W13-254</org_study_id>
    <nct_id>NCT01462877</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic</brief_title>
  <official_title>An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Statin-fenofibrate Combination Therapy in Dyslipidemic Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rundo International Pharmaceutical Research &amp; Development Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherogenic dyslipidemia includes patients who have coronary heart disease (CHD) or CHD risk
      equivalents, whose TG level is not adequately controlled after statin monotherapy. According
      to the published ESC/EAS consensus, fibrate is suggested to be added to this type of patient
      who has insufficient improvement. The purpose of the study is to evaluate the efficacy on
      lipid control and the safety of adding fenofibrate in patients on a background of statin
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is an open-label , single group, multi-center study. At around 30 investigate sites, 500
      dyslipidemic Chinese patients with coronary heart disease (CHD) or CHD risk equivalent, whose
      TG ≥1.70 mmol/L (150mg/dl) and &lt;5.65mmol/L (500mg/dl) after at least 2 month statin
      monotherapy with standard dose will be enrolled. After at least 2 month statin monotherapy
      with standard dose, patients having high TG will be recruited and given statin-fenofibrate
      combination therapy for 8 weeks. Several lipid parameters and safety parameters will be
      compared between baseline, after 4 weeks treatment and after 8 weeks treatment. Primary
      efficacy endpoint is the percentage of TG decrease before and after 8 weeks treatment.
      Secondary endpoints on efficacy are the absolute change and the percent of change on TC,
      LDL-C, HDL-C, apoA1, apoB and apoB/apoA1 of baseline, after 4 weeks treatment and 8 weeks
      treatment, absolute change and percentage of change of hsCRP from baseline to 8 weeks of
      treatment. Second endpoints on safety is the incidence of AE/SAE, change on CK, ALT, AST, BUN
      and Cr before and after treatment and the number of clinical meaningful abnormal change
      defined as ALT or AST &gt;3ULN, or CK &gt;10ULN, or BUN &gt;1.5ULN or Cr &gt;1.5ULN. Other Arm type is a
      self comparator
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Triglyceride (TG) Change</measure>
    <time_frame>Baseline and up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Total Cholesterol</measure>
    <time_frame>Baseline and up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Low-density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum High-density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Non-high-density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Apolipoprotein A1</measure>
    <time_frame>Baseline up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Apolipoprotein B</measure>
    <time_frame>Baseline up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Alanine Aminotransferase</measure>
    <time_frame>Baseline up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Aspartate Aminotransferase</measure>
    <time_frame>Baseline up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatine Kinase</measure>
    <time_frame>Baseline up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>Baseline up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum High Sensitivity C-reactive Protein</measure>
    <time_frame>Baseline and up to 8 weeks after intervention</time_frame>
    <description>Blood tests</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">506</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Fenofibrate arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>Fenofibrate Capsule 200mg qd orally</description>
    <arm_group_label>Fenofibrate arm</arm_group_label>
    <other_name>ABT-799</other_name>
    <other_name>lipanthyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years and &lt; 80 years, male or female

          2. With at least one risk of coronary heart disease (CHD) [medical history of myocardial
             infarction (MI) or coronary angiography shows coronary stenosis ≥ 50% or post
             percutaneous coronary intervention (PCI) or post coronary artery bypass grafting
             (CABG)] or CHD risk equivalents, which comprise,

               -  Other clinical forms of atherosclerotic disease (ischemic stroke, peripheral
                  arterial disease, abdominal aortic aneurysm, and symptomatic carotid artery
                  disease)

               -  Type 2 Diabetes

               -  Multiple risk factors that confer a 10-year risk for CHD &gt;20%.

          3. ≥ 2 months statin monotherapy with standard dose (atorvastatin ≤20mg q.d. or
             rosuvastatin ≤10mg q.d. or simvastatin ≤40mg q.d. or pravastatin ≤40mg q.d. or
             pitavastatin ≤4mg q.d or fluvastatin ≤80mg q.d. or lovastatin ≤40mg q.d.) and plan to
             continue the previous type and dose of statin

          4. Triglycerides (TG)≥1.70 mmol/L (150mg/dl) and TG&lt;5.65 mmol/L (500mg/dl)

          5. Subject must be able to provide informed consent, approved by an Independent Ethics
             Committee (IEC)/Institutional Review Board (IRB), on his or her own behalf, prior to
             any study-specific procedures.

        Exclusion Criteria:

          1. Hypersensitive to fenofibrate or to any of its excipients

          2. Hepatic insufficiency [alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) &gt; 2ULN (upper limit of normal)]

          3. Renal insufficiency [Creatinine clearance rate (Ccr)&lt;60ml/min estimated from
             Cockcroft-Gault equation Ccr=(140-age)*weight(Kg)*0.85(if female)/[0.818*Cr (µmol/L)]

          4. Creatine kinase (CK) &gt; 2 ULN

          5. Congenital galactosemia, glucose-galactose malabsorption syndrome or lactase
             deficiency

          6. Hypothyroidism

          7. Combination use of other non-statin lipid-regulating drugs such as fibrates, niacin
             and fish oil in previous 2 months

          8. Combination use of drug with similar structure as Fenofibrate, especially ketoprofen

          9. Combination use of oral anticoagulants

         10. Pregnant or lactating woman

         11. Other conditions at investigator's discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyra Xie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 64695</name>
      <address>
        <city>Xiamen</city>
        <zip>36100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>October 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2011</study_first_posted>
  <results_first_submitted>February 6, 2015</results_first_submitted>
  <results_first_submitted_qc>February 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>February 25, 2015</last_update_submitted>
  <last_update_submitted_qc>February 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipid Regulating Agents</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>cardiovascular diseases</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <keyword>fenofibrate</keyword>
  <keyword>Dyslipidemias</keyword>
  <keyword>Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dyslipidemic Chinese patients with CHD or CHD equivalent, whose TG ≥1.70 mmol/L and &lt;5.65mmol/L after at least 2 month statin monotherapy with standard dose were enrolled. After at least 2 month statin monotherapy with standard dose, patients having high TG were recruited and given statin-fenofibrate combination therapy for 8 weeks.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fenofibrate Arm</title>
          <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="506"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="492"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-protocol Set</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="435"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>Fenofibrate Arm</title>
          <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="468"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.93" spread="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.54" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Triglyceride (TG) Change</title>
        <description>Blood tests</description>
        <time_frame>Baseline and up to 8 weeks after intervention</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Triglyceride (TG) Change</title>
          <description>Blood tests</description>
          <population>Full Analysis Set</population>
          <units>percentage of TG change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.12" spread="33.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Total Cholesterol</title>
        <description>Blood tests</description>
        <time_frame>Baseline and up to 8 weeks after intervention</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Total Cholesterol</title>
          <description>Blood tests</description>
          <population>Full analysis set</population>
          <units>percentage of TC change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="24.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Low-density Lipoprotein Cholesterol</title>
        <description>Blood tests</description>
        <time_frame>Baseline up to 8 weeks after intervention</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Low-density Lipoprotein Cholesterol</title>
          <description>Blood tests</description>
          <population>Full analysis set</population>
          <units>percentage of LDL-C change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.91" spread="39.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum High-density Lipoprotein Cholesterol</title>
        <description>Blood tests</description>
        <time_frame>Baseline up to 8 weeks after intervention</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum High-density Lipoprotein Cholesterol</title>
          <description>Blood tests</description>
          <population>Full analysis set</population>
          <units>percentage of HDL-C change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.40" spread="32.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Non-high-density Lipoprotein Cholesterol</title>
        <description>Blood tests</description>
        <time_frame>Baseline up to 8 weeks after intervention</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Non-high-density Lipoprotein Cholesterol</title>
          <description>Blood tests</description>
          <population>Full analysis set</population>
          <units>percentage of Non-HDL-C change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="28.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Apolipoprotein A1</title>
        <description>Blood tests</description>
        <time_frame>Baseline up to 8 weeks after intervention</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Apolipoprotein A1</title>
          <description>Blood tests</description>
          <population>Full analysis set</population>
          <units>percentage of apoA1 change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.41" spread="28.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Apolipoprotein B</title>
        <description>Blood tests</description>
        <time_frame>Baseline up to 8 weeks after intervention</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Apolipoprotein B</title>
          <description>Blood tests</description>
          <population>Full analysis set</population>
          <units>percentage of apoB change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="50.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Alanine Aminotransferase</title>
        <description>Blood tests</description>
        <time_frame>Baseline up to 8 weeks after intervention</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Alanine Aminotransferase</title>
          <description>Blood tests</description>
          <population>Safety set</population>
          <units>percentage of ALT change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-72.92" upper_limit="1118.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Aspartate Aminotransferase</title>
        <description>Blood tests</description>
        <time_frame>Baseline up to 8 weeks after intervention</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Aspartate Aminotransferase</title>
          <description>Blood tests</description>
          <population>Safety set</population>
          <units>percentage of AST change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.91" lower_limit="-77.73" upper_limit="676.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatine Kinase</title>
        <description>Blood tests</description>
        <time_frame>Baseline up to 8 weeks after intervention</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatine Kinase</title>
          <description>Blood tests</description>
          <population>Safety set</population>
          <units>percentage of CK change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.02" lower_limit="-73.94" upper_limit="1429.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <description>Blood tests</description>
        <time_frame>Baseline up to 8 weeks after intervention</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Arm</title>
            <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <description>Blood tests</description>
          <population>Safety set</population>
          <units>percentage of Creatinine change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.99" lower_limit="-63.63" upper_limit="80.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum High Sensitivity C-reactive Protein</title>
        <description>Blood tests</description>
        <time_frame>Baseline and up to 8 weeks after intervention</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks + 1 month</time_frame>
      <desc>Serious Adverse Events were collected after Informed Consent was signed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fenofibrate Arm</title>
          <description>fenofibrate: Fenofibrate Capsule 200mg qd orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="492"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="492"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="492"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="492"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="492"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="492"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="492"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="492"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="492"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="492"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="492"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="492"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="492"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director Clinical Services</name_or_title>
      <organization>Abbott</organization>
      <email>taco.baardman@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

